Swedbank AB Trims Position in Mineralys Therapeutics, Inc. $MLYS

Posted by Brenda Bartman on May 27th, 2026

Swedbank AB cut its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Free Report) by 26.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 221,400 shares of the company’s stock after selling 77,900 shares during the quarter. Swedbank AB’s holdings in Mineralys Therapeutics were worth $8,035,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of MLYS. Farallon Capital Management LLC bought a new position in shares of Mineralys Therapeutics during the third quarter worth $63,442,000. Holocene Advisors LP bought a new position in shares of Mineralys Therapeutics during the third quarter worth $45,708,000. RA Capital Management L.P. boosted its position in shares of Mineralys Therapeutics by 19.1% during the third quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock worth $277,717,000 after acquiring an additional 1,176,470 shares during the last quarter. Polar Capital Holdings Plc bought a new position in shares of Mineralys Therapeutics during the third quarter worth $40,149,000. Finally, Jennison Associates LLC boosted its position in shares of Mineralys Therapeutics by 234.4% during the fourth quarter. Jennison Associates LLC now owns 1,258,653 shares of the company’s stock worth $45,677,000 after acquiring an additional 882,307 shares during the last quarter. Institutional investors own 84.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen lowered shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Jefferies Financial Group restated a “hold” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a research report on Friday, March 13th. Bank of America upped their target price on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, TD Cowen assumed coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They set a “buy” rating for the company. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $49.33.

Check Out Our Latest Stock Report on Mineralys Therapeutics

Mineralys Therapeutics Stock Up 0.5%

MLYS stock opened at $29.99 on Wednesday. Mineralys Therapeutics, Inc. has a 52 week low of $12.59 and a 52 week high of $47.65. The company has a fifty day simple moving average of $27.28 and a two-hundred day simple moving average of $32.01. The firm has a market capitalization of $2.47 billion, a P/E ratio of -14.63 and a beta of 0.49.

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.51) by $0.04. As a group, analysts anticipate that Mineralys Therapeutics, Inc. will post -2.3 EPS for the current year.

Insider Buying and Selling at Mineralys Therapeutics

In other Mineralys Therapeutics news, Director Ra Capital Management, L.P. acquired 310,700 shares of the stock in a transaction on Friday, March 27th. The stock was acquired at an average price of $23.67 per share, for a total transaction of $7,354,269.00. Following the completion of the transaction, the director directly owned 5,767,221 shares of the company’s stock, valued at $136,510,121.07. This trade represents a 5.69% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jon Congleton sold 75,000 shares of the stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $26.27, for a total transaction of $1,970,250.00. Following the transaction, the chief executive officer owned 705,051 shares of the company’s stock, valued at $18,521,689.77. This trade represents a 9.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 162,291 shares of company stock worth $4,353,683 over the last three months. 18.94% of the stock is owned by company insiders.

Mineralys Therapeutics Company Profile

(Free Report)

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.